Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D., as Global R&D President Clover Biopharmaceuticals announces Nicholas Jackson, Ph.D., as President of Global R&D and Alliances to spearhead vaccine development and collaborations.

Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D., as Global R&D President #China #Shanghai #Vaccine_Development #Clover_Biopharma #Nicholas_Jackson

Clover Biopharmaceuticals Reveals Promising Phase I Data for Combination RSV Vaccines Clover Biopharmaceuticals shared encouraging Phase I trial results for their innovative combination RSV vaccines, which may significantly improve protection for older adults.

Clover Biopharmaceuticals Reveals Promising Phase I Data for Combination RSV Vaccines #China #Shanghai #RSV_Vaccine #Clover_Biopharma #PIV3_vaccine

Clover Biopharmaceuticals Begins Phase I Trials for New RSV and hMPV Vaccine Candidates Clover Biopharmaceuticals has launched a Phase I clinical trial for SCB-1022 and SCB-1033, a promising combination vaccine for RSV, hMPV, and PIV3 aimed at addressing respiratory diseases.

Clover Biopharmaceuticals Begins Phase I Trials for New RSV and hMPV Vaccine Candidates #China #Shanghai #RSV_Vaccine #Clover_Biopharma #Phase_I_Trials

Clover Biopharmaceuticals Receives IND Clearance for RSV Vaccine SCB-1019 and Starts Revaccination Study Clover Biopharmaceuticals has announced the U.S. IND clearance for its RSV vaccine candidate SCB-1019, marking the commencement of Phase I revaccination trials targeting older adults.

Clover Biopharmaceuticals Receives IND Clearance for RSV Vaccine SCB-1019 and Starts Revaccination Study #Shanghai #United_States #RSV_Vaccine #Clover_Biopharma #SCB-1019